DiaSorin stock rating upgraded to Buy at UBS on growth potential

UBS has upgraded DiaSorin SpA to Buy from Neutral, raising its price target to EUR98.00, despite the stock's 20% year-to-date decline driven by investor concerns over near-term guidance and midterm growth. UBS dismisses these fears, citing DiaSorin's 7% organic revenue growth from a strategic pivot and projecting the company will meet its FY25 guidance and achieve a 7% midterm revenue CAGR by accelerating growth in 2026. The upgrade suggests a significant re-evaluation of DiaSorin's prospects, as UBS believes the market is overestimating end-market saturation and underpricing future catalysts.

Analysis

UBS has issued a contrarian upgrade for DiaSorin SpA to 'Buy' from 'Neutral', raising its price target to EUR98.00 from EUR95.00. This move stands in stark contrast to the stock's 20% year-to-date decline, which has been driven by investor skepticism regarding the feasibility of near-term guidance and the sustainability of midterm growth. UBS refutes these concerns as unjustified, highlighting the company's delivery of 7% organic revenue growth over the last 18 months—a rate above the market average—which it attributes to a successful strategic pivot into underpenetrated market niches. The bank's deep-dive analysis leads it to forecast that DiaSorin will meet its FY25 guidance, albeit potentially at the lower end, and projects an acceleration in 2026 that will drive a 7% midterm revenue compound annual growth rate. UBS contends that the current share price has priced in substantial downgrades that are unlikely to materialize, arguing that end-markets are not as saturated as feared and that a 'rich catalyst path' is being overlooked.

Key Decisions for Investors

• Investors aligned with a value or contrarian strategy could view the 20% year-to-date share price decline as a compelling entry point, given UBS's assessment that the stock is mispriced and poised for a re-rating.
• Monitor upcoming earnings for confirmation that DiaSorin can meet at least the lower end of its FY25 guidance, as this would be the first key test of UBS's bullish thesis against prevailing market sentiment.
• Cautious investors should seek tangible evidence of the 'rich catalyst path' or the projected 2026 growth acceleration before increasing exposure, as the market's current concerns about growth sustainability remain a primary risk factor.